Very soon after the publication of the FY2018 data on this topic, FDA released the data from FY2019 which we address here. We examine data from FY2019 and a total of five years’ worth of trends in GMP inspection enforcement in this area. The regulations that govern this area, 21 CFR 1271, are the same regulations that govern segments of human cell therapy and gene therapy products. Human Cell and Gene Therapy products are part of FDA’s Regenerative Medicine framework.

The presentation of data herein differs from how it is presented on the FDA website, even though it uses the same raw data. For example, I combine all observation listings within a given section that cite 21 CFR 1271 into a single value. §1271.47(a) and §1271.47(b) are consolidated into a single line item, §1271.47. Similar consolidation is done for each of the §1271 citations identified in Figure 4.

Consolidating the citations leads to slightly different conclusions. In my opinion, sometimes slicing the observations so narrowly, as the FDA does, can dilute their impact.

[NOTE: No need to come back to reference this data—download a copy of this report for yourself here!]

The FDA’s data includes only Form 483s issued through its electronic system. Thus, the data does not represent the FDA’s complete collection of inspection observations for the year, and conclusions should be tempered by this limitation. 

Many of the firms that are cited under §1271 are fertility clinics and the ever-increasing number of mostly unlicensed stem cell therapy firms.  Many stem-cell firms do not produce minimally manipulated or homologous use cells, yet they continue to distribute them commercially and run afoul of the FDA, including several firms that received warning letters. Firms governed by §1271 that received warning letters in FY2019 include the following:

Most recently in December 2019, FDA FY2020, Liveyon Labs Inc received a warning letter and FDA also published a press release explaining this warning letter.

The FDA published detailed guidance in November 2017 defining what constitutes minimally manipulated and homologous use in an effort to encourage stem cell firms to come into compliance and file the necessary INDs and BLAs for product approval. It also provides FDA’s Compliance and Enforcement Policy, in section V.B., for this group of products. This year Congress has expressed frustration with the slow pace of firms coming into compliance with requirements and expectations. FDA announced it is exercising “enforcement discretion” for three years after the governing guidance was published, and it is only taking action when the products pose a clear public health risk. Fortunately for FDA, the courts have upheld FDA’s authority in this area in a decision issued in June 2019. It seems that few of the firms are submitting INDs even though this grace period will be over in late 2020, likely because too much money can be made in this area. It will be worth watching to see if there is a flurry of enforcement actions against these firms at the end of the enforcement discretion period, in November 2020.

Executive Summary

Human Tissue Transplantation firms continue to receive only a fraction of the Form 483s issued to drug firms, and with the exception of FY2017 the number of 483s in this area has gradually increased. Particularly in FY2018, the number of Form 483s increased approximately 60 percent over FY2017 and the values continued to increase again in FY2019.

FY2017 appears to be an anomaly when considering the five years covered in this analysis. The total number of Form 483s was substantially lower that year. It was, however, the only year of the five covered here where the number of observations regarding Good Tissue Practices exceeded the number of observations for failure to meet donor eligibility requirements.

Observations in the area of Donor Eligibility (§1271 Subpart C) clearly outpace the number of observations in the area of Current Good Tissue Practices (§1271 Subpart D) in all years except for FY2017.

The number of observations addressing Good Tissue Practices more than doubled in FY2019 from FY2018. The number of observations addressing Donor Eligibility Requirements decreased from 2018 to 2019 though it remains higher than in the other years covered in Figures 2 and 3.

FDA Form 483 Inspection Observations

Figure 1 shows the number of Form 483s that have been issued in this product category over the last five fiscal years. Overall, eliminating FY2017, the number of 483s issued has gradually increased since FY2015 and I expect the number to continue to increase in FY2020. 

Figure 2 presents the total number of observations for Subpart C and Subpart D from FY2015 through FY2019. Figure 3 shows the same data in a graphical presentation. For all years except for 2017, observations associated with Donor Eligibility Requirements far more exceeded those for observations associated with Good Tissue Practices. In FY2019 as in FY2016, the number of Good Tissue Practices observations approached the number of observations for Donor Eligibility Requirements and has more than doubled from the values in FY2018. 

Figure 4 shows the five most frequent inspection citations for Donor Eligibility requirements, Subpart C, and for Good Tissue Practice requirements, Subpart D, between FY2015 and FY2019. The areas that are new to the top five this year are highlighted in bold. This year, §1271.85 is new to the top five, and §1271.80 is no longer among the top five observations associated with Donor Eligibility.

Changes to the top five in Current Good Tissue Practices also appeared in FY2019. New to the group are §1271.200 and .270 replacing §1271.160 and .320. The relative numbers are small for most regulations cited in the observations and I expect changes to happen from year to year in the top five for both groups.

Figures 5 and 6 provide more granularity regarding the top five areas cited for both Donor Eligibility and CGTP based on values from FY2019. Figure 5 provides the five most frequently cited sections for observations addressing Donor Eligibility. In all sections cited, FY2019 values are decreased from those of FY2018 though, for three of the areas, §1271.75, §1271.47, and §1271.85, the value in FY2019 remained significantly above other years.

Figure 6 shows marked increases in all five most frequent citations for Current Good Tissue Practices for FY2019 when compared to FY2018. In two instances, §1271.265 and §1271.180, the values are lower than in one or two of the previous years. It is noteworthy that observations associated with the requirement to establish and maintain a quality program are no longer in the top five in FY2019.

Conclusions

Human Tissue Transplantation includes important areas for current and future GMP inspections, reflecting the increase in the number of gene and cell therapy firms, and stem cell clinics, including those which are not licensed. When enforcement discretion for stem cell clinics ceases in late 2020, we should expect a surge in inspections of these firms and subsequent enforcement actions including warning letters and possibly seizures.

This area can be complicated from a GMP perspective and includes the intersection of §1271 and §211, the GMPs for drug products, depending on the nature of the cell- or tissue-based product. The number of inspections, with the exception of FY2017, has increased over the past five years. The inspection focus for this group of products is primarily in the area of donor eligibility and the failure to document or perform adequate testing and medical record review of the donor. The potential infectious disease risks posed by human tissue or cell donations are the basis for this focus.

CGTP observation frequency comes in a distant second to those in the area of donor eligibility. It will be useful to see if this trend continues in the coming years as more gene and cell therapies reach commercialization and stem cell clinics must conform to these requirements.

[NOTE: No need to come back to reference this data—download a copy of this report for yourself here!]

Human Factors – Compliance and Applications

June webinar

Presented by Alison Sathe, Founder, Regulatory Mark & Valerie Fenster, Director of Insights and  Human Factors, Kaleidoscope Innovation 

June 29, 1:30 p.m. EST

What you will learn:

  • Human factors strategies from simple drug products to complex surgical devices
  • Primary and secondary labeling development and evaluation for usability
  • Human factors activities from product development to post-market
  • International strategies: expectations for human factors in regulatory submissions in international markets

Panel Discussion – Remote Audits

Panel Discussion opt in image

Featuring Panelists:
—Barbara W. Unger, Unger Consulting, Inc.
—Jerry Chapman, Redica Systems
—Stephanie Gaulding, Pharmatech Associates

Who Will Benefit?
This session will be valuable to GMP quality, regulatory, compliance, and management personnel in FDA-regulated industries who want to have a conversation on remote audits and get to know what is going on in the industry.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore observations and trends. 

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to run your custom report.

Redica Systems Enforcement Analytics

Get help choosing the right CRO.

Enter your email address and someone will contact you shortly to customize your insights.

Redica Systems Enforcement Analytics

Compare two companies of your choice.

Enter your email address and someone will contact you shortly to customize your report.

Download the Special Report

Download your copy of THE FDA INSPECTION LANDSCAPE IN MID-2020 AND A LOOK AT VIRTUAL INSPECTION

In this summary we identify:

  • Trend analysis of FDA inspections through mid-2020
  • Strategies for preparing and hosting virtual inspections
  • New technologies to support remote inspections

Download the Special Report

CDMO Comparison opt-in

In this summary we identify:

FY2018-FY2020 GMP data for Lonza & Catalent

Top GMP primary citations

Top FDA 483 observations

Turning Failure into Success

Presented on Tuesday, April 27, 2021 by Steve Greer, Executive Coach, Genesis Assist, and former Quality Leader, Procter and Gamble

What you will learn:

  • How to use the Leadership SOS Model to transform quality culture
  • How to strengthen quality systems to eliminate human error
  • How to generate ideas on how to set your organization up for success for shareholders, FDA, and staff
Redica Systems Enforcement Analytics

Prepare for inspections of Clinical Investigator sites.

Enter your email address and someone will contact you shortly to provide more Clinical Investigator data about your sites.

Redica Systems Enforcement Analytics

Get Full Access to Redica Enforcement Analytics

Enter your email address and someone will contact you shortly to answer all of your questions and get you started.

Quality Management Systems for Small Pharma and Biotech Firms

Webinar: QMS for Small Pharma and Biotech Firms

Presented by Fenton Fong, Founder, Managing Director, & Principal at xCellarate

Get instant access to the webinar video and slides.

What you will learn:

  • Common challenges small pharma firms face when developing a QMS
    Recent enforcement trends involving the Quality Unit
    Impact of the COVID-19 pandemic

Download the Special Report

APAC ad

In this summary we identify:

GMP data from FY2017 to FY2020 for the Asia-Pacific region

Top 3 GMP primary and secondary citations

Top 3 483 observations

Download the Special Report

An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report

In this summary we identify:

  • Data from 2019 UK MHRA Inspections
  • Trends from 2015, 2016, 2018, and 2019 inspections
  • Conclusions drawn from an analysis of drug inspection data

Experience the Power of Redica Systems

Redica Pro Free

Sign up for your FREE account today and get instant access to:

SEARCH Find the inspection records you want by inspector’s name, company name, site, city, country, etc.

WARNING LETTERS Easily search the largest database of FDA Warning Letters by date, company, FDA office, or subject

SITES Quickly assess inspection records including dates and inspectors across all of your sites

INSPECTIONS Complete list of FDA inspections by date, company, category, and country

Get Complete Access to the Redica Systems Platform

Please submit your email address and one of our team members will contact you shortly to answer all of your questions and get you started with the new Enforcement Analytics platform.

Redica Systems Enforcement Analytics

Prepare for your next inspection.

Enter your email address and someone will contact you shortly to explore enforcement trends. 

Redica Systems Enforcement Analytics

Monitor compliance at your Clinical Investigator sites.

Enter your email address and someone will contact you shortly to get you started.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Let us know who you are and we’ll be in touch to answer all of your questions and get you started.

Redica Systems Enforcement Analytics

Upgrade your CDMO monitoring strategy.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Keep up with the latest Regulatory Developments on Clinical Trials

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save your team valuable time when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Save time and Resources when using External Monitoring.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Get immediate access to the news that matters to your sites.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

See how we can help you eliminate yet another spreadsheet.

Enter your email address and someone will contact you shortly. 

Redica Systems Enforcement Analytics

Stay ahead of changing regulations.

Enter your email address and someone will contact you shortly to get the data and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your CDMO management strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Compare the enforcement history of your CDMOs.

Enter your email address and someone will contact you shortly to customize your report.

Experience the Power of Redica Systems

Redica Systems Enforcement Analytics

Sign up for your FREE account today and get instant access to Enforcement Analytics.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need.

Redica Systems Enforcement Analytics

Upgrade your inspection strategy.

Enter your email address and someone will contact you shortly to get the reports and analysis you need to prepare for your next inspection.

Experience the Power of Redica Systems

Complete the form and one of our experts will reach out to you to schedule a demo and answer questions about our subscription options.

INDEX INFORMATION  Redica consolidates regulatory data in real-time on the single largest database for quality, safety, and compliance intelligence.

STRENGTHEN DATASETS Redica machine intelligence algorithms identify and triage risk signals to derive meaning from vast amounts of private and public data.

ANALYZE & INTERPRET PATTERNS Redica instantly models the customer-specific regulatory risks, trends, and opportunities that stand to fundamentally change compliance operations.

Redica Systems Enforcement Analytics

Evaluate Your CDMOs

Enter your email address and someone will contact you shortly to customize your report.

Redica Systems Enforcement Analytics

Compare the inspection history of your CDMO sites.

Enter your email address and someone will contact you shortly to customize your report.

Discover the power of the most comprehensive database of 483s in existence.

Our database of over 20,000 483s is retyped and tagged, making it easy to create an Observation Report in seconds.

Eliminate days of work and get your FREE personalized 483 Observation Report.